Fig. 5
HER2-TAC-T cells demonstrate an enhanced safety profile and improved efficacy over first- and second-generation HER2-CAR-T cells in vivo. OVCAR-3 tumor-bearing mice are treated with 2.0 × 106 HER2-TAC-T cells (a), first-generation anti-HER2 CAR-T cells (b), second-generation anti-HER2 28ζ CAR-T cells (c), or a matched total number of vector control T cells (d). Mice are followed for change in body weight and tumor volume; each curve represents a single treated mouse relative to pre-treatment weight/volume. When mice reach endpoint, this is indicated via X in (c). Data has been replicated in an independent experiment. Using curve fitting analysis and multiple t-test HER2-TAC induced regression is significantly different from control, 1st, and 2nd generation CAR curves, while tumor growth between vector control and 1st gen CAR was not significantly different. The change in body weight observed in 2nd gen CAR curves is significantly different from vector control, 1st gen CAR, and TAC-T cell treated mice. However, the difference in body weight between vector control, 1st gen CAR, and TAC curves was not significantly different
